CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
Boosted atazanavir +1 moredrug
Likely dose
Boosted atazanavir 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02652793
NCT02652793N/ACompleted
CompareCT.gov

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

Judit Pich·interventional·Posted Jan 12, 2016·Updated Jul 2, 2025

In Brief

A clinical study evaluating Boosted atazanavir and Lamivudine for Human Immunodeficiency Virus. Completed, enrolled 31 participants across 1 site.

Detailed Summary

A 48-week, open label, non comparative prospective trial in stable chronic human immunodeficiency virus-infected patients having achieved complete virological suppression for more than 24 weeks (human immunodeficiency virus-1 RNA \<50 c/ml) switching from an antiretroviral regimen containing tenofovir and lamivudine or emtricitabine and boosted protease inhibitor to boosted atazanavir and lamivudine Study visits will take place at screening, baseline, weeks 4, 12, 24, and 48.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesSpain
CollaboratorsFundacion Clinic per a la Recerca Biomédica

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 12, 2016
Enrollment StartNov 1, 2015
Primary CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 10.5 years ago

Interventions

Boosted atazanavirdrug

Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly

Lamivudinedrug

Lamivudine 300 mg once dailly